Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study

Chad Moretz,1 Lucie Sharpsten,2 Lindsay GS Bengtson,2 Eleena Koep,2 Lisa Le,2 Junliang Tong,2 Richard H Stanford,1 Beth Hahn,1 Riju Ray31US Value Evidence and Outcomes, GSK, Durham, NC, USA; 2Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA; 3US Medical Affairs, GSK, Durham, NC,...

Full description

Bibliographic Details
Main Authors:	Moretz C, Sharpsten L, Bengtson LGS, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-08-01
Series:	International Journal of COPD
Subjects:	COPD LAMA/LABA ICS/LABA real-world effectiveness retrospective cohort
Online Access:	https://www.dovepress.com/real-world-effectiveness-of-umeclidiniumvilanterol-versus-fluticasone--peer-reviewed-article-COPD

Similar Items

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
by: Panettieri Jr RA, et al.
Published: (2022-09-01)

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
by: Bruno Balbi
Published: (2015-08-01)

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored
by: Vitalii I. Kupaev, et al.
Published: (2020-06-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021-01-01)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
by: Singh D, et al.
Published: (2019-12-01)

LA inhalers for COPD: perceptions/reality of ABCD GOLD tool use
by: Varvara Boryushkina, et al.
Published: (2020-07-01)

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
by: Requena G, et al.
Published: (2023-07-01)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
by: Yawn BP, et al.
Published: (2021-02-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
by: Yamada H, et al.
Published: (2018-10-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Early COPD diagnosis and treatment: A case report
by: Roberto G. Carbone, et al.
Published: (2023-01-01)

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study
by: Beeh KM, et al.
Published: (2018-12-01)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
by: Soler-Cataluña JJ, et al.
Published: (2023-06-01)

Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada
by: Tavakoli H, et al.
Published: (2019-09-01)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
by: Bourbeau J, et al.
Published: (2021-03-01)

Optimizing bronchodilation in the prevention of COPD exacerbations
by: Marc Miravitlles, et al.
Published: (2017-06-01)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
by: Braghiroli A, et al.
Published: (2020-06-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
by: Czira A, et al.
Published: (2023-04-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
by: Rogliani P, et al.
Published: (2018-10-01)

Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
by: Moretz C, et al.
Published: (2019-09-01)

Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
by: Jean Bousquet, et al.
Published: (2017-04-01)

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2022-12-01)

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial
by: Oliver Amanda, et al.
Published: (2012-06-01)

Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?
by: Paolo Solidoro, et al.
Published: (2022-03-01)

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study
by: David Slade, et al.
Published: (2021-07-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)